Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo‐controlled clinical trials
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Objective: To examine the safety and tolerability of the antidepressant duloxetine across multiple studies for major depressive disorder (MDD). Method: Safety data were integrated from the acute phases of eight double‐blind, placebo‐controlled trials in which patients were randomized to duloxetine (40–120 mg/d; n = 1139) or placebo (n = 777) for up to 9 weeks. This data set included all acute‐phase clinical trials that formed the basis of the New Drug Application (United States) or European Union submission package for duloxetine in the treatment of MDD. Two studies included continuation phases in which acute treatment responders received duloxetine or placebo for an additional 26 weeks. Safety assessments included serious adverse event reports, rates of discontinuation, spontaneously reported treatment‐emergent adverse events, changes in vital signs and laboratory values, and electrocardiograms. Results: The rates of serious adverse events for duloxetine‐ and placebo‐treated patients were 0.3% and 0.6%, respectively (p = 0.282). Adverse events led to discontinuation in 9.7% of duloxetine‐treated patients, compared with 4.2% of patients receiving placebo (p < 0.001). Treatment‐emergent adverse events with an incidence for duloxetine ≥ 5.0% and significantly greater than placebo were nausea, dry mouth, constipation, insomnia, dizziness, fatigue, somnolence, increased sweating and decreased appetite. Mean changes in blood pressure and heart rate were small, and the incidence of increases above normal ranges was low. Duloxetine‐treated patients had a mean decrease in weight of 0.5 kg compared with an increase of 0.2 kg for patients receiving placebo (p < 0.001). No significant differences were found between duloxetine and placebo in the incidence of potentially clinically significant laboratory values at anytime while on treatment. Conclusion: These results are consistent with those obtained previously from smaller pooled data sets, and suggest that duloxetine is safe and well tolerated in patients with MDD. Copyright © 2005 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anderson, I. M. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00092-0 · Cited by 940
SSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669 · cited 2×
“However, longer-term therapy has been associated with treatment-emergent sexual dysfunction and weight gain, which may adversely affect patient compliance (Ferguson, 2001).”
Montejo-gonzàlez, A. L., Llorca, G., Izquierdo, J. A., Ledesma, A., Bousono, M., Calcedo, A., Carrasco, J. L., Ciudad, J., Daniel, E., De LA Gandara, J., et al. (1997) · Journal of Sex & Marital Therapy · doi:10.1080/00926239708403923 · Cited by 505 · cited 1×
“One study of antidepressant-induced sexual dysfunction found an incidence of 58% when patients were directly questioned, as opposed to 14% when dysfunction was assessed using spontaneously reported adverse events (Montejo-Gonzalez et al., 1997).”
Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.
Song, F., Freemantle, N., Sheldon, T. A., House, A., Watson, P., Long, A., & Mason, J. (1993) · BMJ · doi:10.1136/bmj.306.6879.683 · Cited by 399 · cited 1×
“The favorable safety profile of the SSRIs was in large part responsible for their acceptance as the first-line therapy for the treatment of depression (Edwards and Anderson, 1999; Ferguson, 2001; Song et al., 1993).”
Detke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384 · cited 2×
“Summaries of efficacy and safety data from studies 1 (Detke et al., 2002a), 2 (Detke et al., 2002b), 3 (Goldstein et al., 2002), 6 (Goldstein et al., 2004) and 7(Detke et al., 2004) have been published previously.”
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334 · cited 4×
“Comparisons of the efficacy and safety of duloxetine with that of paroxetine and fluoxetine have been presented elsewhere (Goldstein et al., 2002; Tran et al., 2003).”
InfluentialSelf-citationThase, M. E. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1002 · Cited by 331 · cited 1×
“The utility of the repeated measures method for the analysis of BP in the presence of patient attrition over time has been discussed by Thase (1998).”
Goldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314
Self-citationPeretti, S., Judge, R., & Hindmarch, I. (2000) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2000.tb10944.x · Cited by 236
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214 · cited 5×
“In particular, SSRIs exhibit considerably greater safety in overdose (Barbey and Roose, 1998).”
Influential
Cited by
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Chekroud, A. M., Gueorguieva, R., Krumholz, H. M., Trivedi, M. H., Krystal, J. H., & McCarthy, G. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0025 · Cited by 276
Does Treatment With Duloxetine for Neuropathic Pain Impact Glycemic Control?
Hardy, T., Sachson, R., Shen, S., Armbruster, M., & Boulton, A. J. M. (2007) · Diabetes Care · doi:10.2337/dc06-0947 · Cited by 79
Nierenberg, A. A., Ostacher, M. J., Huffman, J. C., Ametrano, R. M., Fava, M., & Perlis, R. H. (2008) · Journal of Occupational & Environmental Medicine · doi:10.1097/jom.0b013e31816b5034 · Cited by 70
Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine
Trivedi, M. H., Desaiah, D., Ossanna, M. J., Pritchett, Y. L., Brannan, S. K., & Detke, M. J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f41d7e · Cited by 59
Choy, E. H. S., Mease, P. J., Kajdasz, D. K., Wohlreich, M. M., Crits-Christoph, P., Walker, D. J., & Chappell, A. S. (2009) · Clinical Rheumatology · doi:10.1007/s10067-009-1203-2 · Cited by 47
“In the treatment of MDD, for example, the incidence of common adverse events has been reported to be generally lower for both placebo and duloxetine than found here [40].”
BackgroundSelf-citationAdverse reactions to duloxetine in depression
Bitter, I., Filipovits, D., & Czobor, P. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.582037 · Cited by 38
“1%) in the duloxetine and placebo groups, respectively [27].”
BackgroundInfluential
Metadata
- Authors
- Hudson, J. I., Wohlreich, M. M., Kajdasz, D. K., Mallinckrodt, C. H., Watkin, J. G., & Martynov, O. V.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2005-05-24
- Volume
- 20
- Issue
- 5
- Pages
- 327-341
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2084168719
- Cited by
- 115
- References
- 12
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.